The MEK1/2-targeted inhibitors cobimetinib (in combination with the BRAF-targeted vemurafenib) and binimetinib (in combination with the BRAF-targeted encorafenib) are approved for the treatment of adults with BRAF V600-mutant unresectable or metastatic melanoma, and the MEK1/2-targeted inhibitor selumetinib is approved for the treatment of pediatric neurofibromatosis type 1. Here, MAP2K1 is linked to neurofibromatosis type 1.